BFEC
JUNO

Benjamin F. Edwards & Company’s Juno Therapeutics, Inc. JUNO Stock Holding History

Benjamin F. Edwards & Company’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,478
Closed -$68K – 1732
2017
Q4 		$68K Buy
1,478
+50
+4% +$2.49K 0.01% 741
2017
Q3 		$64K Sell
1,428
-350
-20% -$11.9K 0.01% 713
2017
Q2 		$53K Buy
1,778
+58
+3% +$1.43K 0.01% 700
2017
Q1 		$38K Buy
1,720
+950
+123% +$20.4K 0.01% 733
2016
Q4 		$15K Sell
770
-490
-39% -$12K ﹤0.01% 859
2016
Q3 		$38K Sell
1,260
-1,700
-57% -$52.9K 0.01% 593
2016
Q2 		$114K Sell
2,960
-125
-4% -$5.19K 0.02% 391
2016
Q1 		$118K Sell
3,085
-1,350
-30% -$47K 0.02% 370
2015
Q4 		$195K Buy
4,435
+100
+2% +$4.96K 0.04% 313
2015
Q3 		$176K Buy
4,335
+3,635
+519% +$159K 0.04% 323
2015
Q2 		$37K Buy
700
+100
+17% +$5.31K 0.01% 659
2015
Q1 		$36K Buy
+600
New +$29.1K 0.01% 636

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Benjamin F. Edwards & Company's JUNO Position: Q1 2018 in Review

Benjamin F. Edwards & Company sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 1,478 shares — an estimated $68K sold.

Benjamin F. Edwards & Company first reported a position in JUNO in Q1 2015 and held it in 12 quarters. The position peaked at $195K in Q4 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Benjamin F. Edwards & Company reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 1,478 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $68K.
  • Benjamin F. Edwards & Company first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 12 quarters.
  • Benjamin F. Edwards & Company's Juno Therapeutics, Inc. position peaked at $195K in Q4 2015.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Benjamin F. Edwards & Company's 13F filing for Q1 2018, filed 17 Apr 2018.